Semaglutide Sodium vs. Semaglutide: The Salt Form Issue

By Alsen Walker · Editorially reviewed on 25 August 2026 · Not medically reviewed by a clinician

Semaglutide sodium and semaglutide acetate are salt forms, and they are not the active ingredient in approved semaglutide products. FDA has raised concerns about their use in compounded preparations. If a product is sold under one of those names, you are not receiving the same substance as the approved medicine, whatever the marketing implies.

For the wider picture on compounded products and how to check a supplier, see Compounded GLP-1s: What They Are and How to Check a Supplier.

What a salt form is

Many drugs exist as salts, which can change solubility, stability or handling. This is ordinary pharmaceutical chemistry and salt forms are not inherently suspect.

What matters is that approval applies to a specific substance. Approved semaglutide products contain semaglutide base. A salt form is a different substance for regulatory purposes, and it has not been through approval in that form.

So the question is not whether salts are bad. It is whether what you are taking is the thing that was studied and approved.

Why it appeared in this market

Compounding rules restrict copies of approved products. A salt form can be presented as not being a copy, which is one reason these products appeared.

Salt forms have also been available through channels supplying compounders when the approved active ingredient was not.

Both explanations are about regulatory positioning rather than clinical benefit to you.

What is not established

Whether a given salt form delivers equivalent active drug at a given dose.

Whether stability and shelf life match.

Whether dosing instructions written for the base apply.

The trials that support semaglutide were conducted with the approved substance. Extending those results to a different salt form is an assumption, not a finding.

The dosing consequence

If the substance differs, the amount of active drug per stated milligram may differ too.

That interacts badly with the wider problem in this market: compounded concentrations vary between pharmacies, and instructions circulate in insulin units rather than milligrams. Uncertainty about the substance on top of uncertainty about the concentration is how significant dosing errors happen.

What to do

Ask your provider, in writing, exactly which substance and concentration you are receiving, and which pharmacy prepared it.

Take that answer to a prescriber who is not selling it to you.

If you cannot get a clear answer, treat that as the answer.

Frequently asked questions

Is semaglutide sodium the same as semaglutide?
No. It is a different substance from the one in approved products.

Does it work?
Not established in the way the approved substance is. Assuming equivalence is an assumption.

Is it dangerous?
The issue is that it is unstudied in this use, and dosing equivalence is unclear. That is different from a known harm.

How do I find out what I have?
Ask your provider in writing. Vagueness is informative.

Why is it sold at all?
Largely regulatory positioning around compounding restrictions.

What if I have been taking it?
Tell a prescriber what you took, and discuss moving to an approved product.